www.fdanews.com/articles/101046-merck-serono-exercises-option-in-aurora-kinase-inhibitor-agreement
Merck Serono Exercises Option in Aurora Kinase Inhibitor Agreement
November 14, 2007
Merck Serono, a division of Merck KGaA, has added Japan to its Aurora kinase collaboration with Rigel, which includes a potential treatment for tumors.
In October 2005, the companies signed a worldwide agreement — excluding Japan — to develop R763/AS703569 and other Aurora kinase inhibitors. As part of this agreement, Merck Serono could add Japan to its territory.
Merck Serono has begun three Phase I trials with R763/AS703569 in patients with solid tumors and leukemia, Rigel said.